Previous

E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference
Next

VentureMed Group Closes $28M Series C Funding to Accelerate CommercialAdoption and Expand Indications for the FLEX VPTM System.